Eisai Co Ltd News, Eisai Co Ltd Quote, ESALF Quote

Eisai Co Ltd (OP:ESALF) Delayed: 27.54 -3.47 (11.19%)

Prev. Close

$31.01

Today 6M 1Y 5Y

Open

$27.54

52 Wk High

$66.25

52 Wk Low

$53.50

Day High

$27.54

Day Low

$27.54

P/E

N/A

EPS

$0.00

Volume

114

Friends, Peers and Foes (?): ESAIY, EII BIIB (more...)

ALERTS | RSS

Jul 27, 2026 02:50 PM Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of Migraine
Jul 17, 2026 07:21 PM EMA accepts Eisai's lemborexant application for insomnia treatment
Jul 17, 2026 07:21 PM Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)
Jul 15, 2026 02:51 PM LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months
Jul 15, 2026 01:29 PM FDA approves Leqembi Iqlik subcutaneous injection for Alzheimer's
Jul 15, 2026 01:29 PM FDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
Jul 15, 2026 01:01 PM Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference(R) (AAIC(R))
Jul 13, 2026 09:22 PM LEQEMBI(R) Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International
Jun 17, 2026 01:15 AM Eisai invests £48M in UK manufacturing with government backing
Jun 17, 2026 01:15 AM Eisai Announces Strategic Investment Supported by the UK Government's LSIMF

Entities mentioned with ESALF

View All Entities